Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Edwards Lifesciences (NYSE: EW) today announced investments that reflect the company’s deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient needs and supporting sustainable long-term...Read the Full Article
enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive high-risk Non-Muscle...Read the Full Article
Positive results including complete inhibition of cough response in preclinical models and a favorable safety profile in three clinical studies support the initiation of a Phase 2b clinical trial of...Read the Full Article
The Extroducer® Infusion Catheter System ® enables local delivery of XC001 to the heart without the need for surgery. XC001 has achieved positive Phase 1/2 results in the EXACT Trial...Read the Full Article
Lumira Ventures, a leading North American life sciences investment firm dedicated to supporting healthcare innovation and patient impact, is pleased to announce the promotion of Nikhil Thatte to the position...Read the Full Article
Oversubscribed financing led by strategic investor, with participation from new and existing investors Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes, announced...Read the Full Article
Cordella, which consists of the now PMA-approved Cordella PA Sensor and commercial Cordella™ HF System, enables comprehensive heart failure management in the home using pulmonary artery (PA) pressure, a leading...Read the Full Article
The Toronto-based biotech startup has the potential to reshape the way we approach pain relief. Every 65 minutes and 22 seconds. That’s how often someone dies from an opioid overdose...Read the Full Article
Designation Supports Accelerated Drug Development for PSPTPN-101 is the First PSP Treatment to Reduce NfL and IL-6 Levels,Key Biomarkers of Neurodegeneration and Neuroinflammation in PSP SAN DIEGO, California, May 21,...Read the Full Article
AmacaThera Inc, a clinical stage biotechnology company specializing in the development of advanced sustained release hydrogel formulations, has dosed its first human subject with AMT-143, the company's lead asset in...Read the Full Article
X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that the U.S. Food and Drug Administration (FDA) has approved XOLREMDI™ (mavorixafor) capsules...Read the Full Article
TORONTO, ON / ACCESSWIRE / APRIL 2, 2024 / Lumira Ventures is delighted to announce its latest investment in Nocion Therapeutics, a clinical-stage biopharmaceutical company developing first and potentially best-in-class,...Read the Full Article
HAMILTON, ON and BOSTON, March 19, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced the Company has entered into a definitive...Read the Full Article
TORONTO, ON / ACCESSWIRE / March 7, 2024 / Lumira Ventures, a life sciences investment firm dedicated to supporting healthcare innovation and patient impact, is proud to announce several significant advancements...Read the Full Article
Iterion Therapeutics, an oncology-focused biopharmaceutical company developing small molecule inhibitors of Transducin beta-like protein 1 (TBL1), a downstream target in the Wnt/beta-catenin signaling pathway, announced today it is actively enrolling...Read the Full Article